In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

J&J is acquiring Centocor

Executive Summary

Johnson & Johnson will acquire Centocor Inc. (monoclonal antibodies) for $4.9bn in stock (0.639 share of J&J for each Centocor share). Centocor's ReoPro, a platelet-inhibiting MAb, will complement the Palmaz-Schatz coronary stents sold by J&J's Cordis unit.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies